IVIEW Therapeutics Inc., a clinical-stage biotechnology company dedicated to advancing innovative treatments for ocular diseases, today announced its participation in the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting. IVIEW will present one oral presentation and four posters highlighting advancments in dry eye, gene therapy, ocular…
Read More
IVIEW Therapeutics Inc. (“IVIEW”), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative ophthalmic therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a Phase 3 clinical trial for IVIEW-1701. IVIEW-1701 is an innovative drug…
Read More
IVIEW Therapeutics announced today that its innovative gene therapy candidate GVB-2001 has successfully completed treatment of the first patient with primary open-angle glaucoma (POAG), marking a key clinical milestone and opening a new chapter for glaucoma management unconstrained by patient-specific genetic backgrounds. The procedure was performed under the direction of…
Read More
IVIEW Therapeutics (“IVIEW”) today announced that its investigational ophthalmic drug, IVIEW-1201D, has received U.S. Food and Drug Administration (FDA) Phase III IND clearance for the treatment of adenoviral conjunctivitis. This important milestone marks the program’s entry into a new phase of global, pivotal clinical development and represents a major step…
Read More
PHILADELPHIA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics, Inc., a clinical-stage immunotherapy company pioneering innovative cell therapies, today announced it will share interim clinical data from its Phase 1 first-in-human study of VIPER-101, a CD5-modulated autologous CAR-T therapy for patients with relapsed or refractory (r/r) T-cell lymphoma (TCL), in…
Read More
IVIEW Therapeutics is pleased to announce the appointment of Jeanette Stewart, RN, as the Director of Clinical Operations Bringing more than 30 years of expertise in ophthalmic clinical research, Ms. Stewart is a seasoned professional who has successfully managed clinical trials across all stages of development. She is the CEO…
Read More
First Patient Dosed in Phase 2b Clinical Trial of IVW-1001 for Dry Eye Disease IVIEW Therapeutics today announced that the first patient has been dosed in its Phase 2b clinical trial evaluating IVW-1001, a novel topical therapy for dry eye disease. The initial dosing was conducted at the Eye Research…
Read More
IVIEW Therapeutics Presents Breakthrough GVB-2001 Gene Therapy for Glaucoma at CCRVO The 13th Congress of Chinese Research in Vision and Ophthalmology (CCRVO), jointly organized by the Chinese Medical Association and its Ophthalmology Branch, was held in Chongqing from July 24–27, 2025. As one of the two premier Category I academic…
Read More
Vittoria Biotherapeutics to Share Trials-in-Progress Presentation from Phase 1 Study of VIPER-101 at ASCO 2025 Annual Meeting Trial is evaluating VIPER-101, a novel, gene-edited, autologous dual-population CAR-T therapy in patients with T-cell lymphoma PHILADELPHIA, May 28, 2025 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics Inc., a clinical-stage immunotherapy company specializing in the development of innovative…
Read More
ImmunoGenesis Doses First Patient in Phase 1/2 Clinical Trial of IMGS-101 in Combination With Balstilimab (anti-PD-1) and Zalifrelimab (anti-CTLA-4) in Relapsed or Refractory Advanced Prostate, Pancreatic, and HPV(-) Head & Neck Tumors IMGS-101 is the only known reducer of solid tumor hypoxia, offering the potential to enhance the efficacy of…
Read More